文传商讯

Takeda’s TAK-861 Phase 2b Late-Breaking Data Presentations at SLEEP 2024 Demonstrate Clinically Mea
2024-06-05 00:13:44

Merck’s Innovative Oncology Pipeline of DNA Damage Response Inhibitors and Antibody-Drug Conjugates
2024-06-05 00:13:44

西班牙Germans Trias i Pujol医院采用Masimo W1 Medical Watch和Radius VSM Wearable Continuous Vital Sig
2024-06-05 00:13:44

Takeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS
2024-06-05 00:13:44

Takeda Receives Positive CHMP Opinion for Recombinant ADAMTS13 (rADAMTS13) in Congenital Thrombotic
2024-06-05 00:13:44